Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$0.12 - $0.3 $7,989 - $19,974
66,581 Added 15.56%
494,520 $59,000
Q3 2022

Nov 14, 2022

SELL
$0.14 - $1.07 $15,793 - $120,704
-112,808 Reduced 20.86%
427,939 $66,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.73 $10,959 - $21,545
-12,454 Reduced 2.25%
540,747 $476,000
Q1 2022

May 13, 2022

BUY
$1.14 - $2.09 $77,273 - $141,668
67,784 Added 13.96%
553,201 $686,000
Q4 2021

Feb 11, 2022

BUY
$1.67 - $2.76 $522 - $863
313 Added 0.06%
485,417 $947,000
Q3 2021

Nov 16, 2021

BUY
$2.62 - $3.45 $28,146 - $37,063
10,743 Added 2.26%
485,104 $1.33 Million
Q2 2021

Aug 16, 2021

BUY
$1.96 - $3.15 $832,184 - $1.34 Million
424,584 Added 852.97%
474,361 $1.5 Million
Q1 2021

May 17, 2021

BUY
$1.89 - $2.96 $94,078 - $147,339
49,777 New
49,777 $107,000

Others Institutions Holding VTGN

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $720M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.